Contact
Home • Our expertise • Business units • How we help clients • Data and insights • IndicationNav

Find your way
with IndicationNav.

Prioritizing indications for assets in clinical trials.

IndicationNav, part of InizioNavigator.ai, supports cross-functional teams to prioritize development opportunities for their assets, by enabling a systematic and rigorous scoring, powered by extensive data and underlying frameworks. It empowers our teams to help you make more confident asset and indication decisions.

 

Powered by People.
Accelerated by AI.

Data and insights are central to what we do. With IndicationNav, an asset indication prioritization tool in our Navigator suite, our teams can quickly identify and prioritize deeper insights to support confident decisions.

Prioritization

Confidence: Find and prioritize indications for a specific asset currently in clinical trials with unprecedented certainty and insights to bring your drug or therapy to laser-targeted patient groups.

Smart decisions: Enables real-time strategic decision making, with the ability to rapidly refresh data in the future.

Let’s Connect

AI-powered speed

Fast decisions: With IndicationNav’s ability to synthesize data from over 200,000 trials, you can be assured of a comprehensive and prioritized data set, to make your decisions, faster.

Real-time: Driven by our consultants, this AI-powered tool refreshes in real-time to present continuously updated data to support the prioritization of indications for assets.

Let’s Connect

Deeper Insights

Nuanced insight: Built for the pharmaceutical industry, leveraging data from thousands of top-performing drug and therapy launches.

Granular detail: Our consultants can deliver deeper insights at a granular level, with a framework and workflows to filter and score development opportunities for a single asset across potential indications.

Let’s Connect

Impact by numbers.

15+

Data sources covered

46

Diseases

~20,000

Unique assets

~200,000

Trials

~3,000

Mechanisms of action

17

In-house algorithms

Experts in Indication Prioritization.

Joseph Feingold

Partner, Portfolio, Licensing & Development Practice Lead & Head of Advanced Technologies Center of Excellence, Putnam

A neuroscientist turned biotech strategy expert with deep experience navigating complex challenges in global markets, Joseph combines scientific and entrepreneurial skillsets to perform rigorous analysis and deliver critical insights to biopharma, diagnostics, and medical device leaders.

Joseph supports a range of clients across therapeutic areas and modalities, with particular focus on hematology / oncology, neurology, and rare diseases, developing strategies for pipeline products and portfolios to guide BD, clinical development, and commercialization. An expert on novel technologies, Joseph heads Putnam’s center of excellence on advanced technologies, including cell and gene therapies, requiring sophisticated hospital-based administration and development of new commercialization models.

Read more

John L’Ecuyer

Executive Director, Business Development, Putnam

As part of Putnam’s Portfolio, Licensing & Development practice, John helps clients build clinical development and go-to-market strategies.

Across therapy areas, he has helped clients drive strategic prioritization decisions about where to position their early-stage assets in the future treatment paradigm, how to determine the target profile and clinical development path required to win and differentiate, and how to size the opportunity and weigh trade-offs.

He joined SmartAnalyst (now part of Putnam) in 2003 and has partnered with biopharma clients in North America, Europe, and Asia-Pacific to provide data-driven strategies and insights that inform important clinical development and investment decisions. Prior to SmartAnalyst, he worked in healthcare communications, where he supported media relations for healthcare providers and biotech companies.

Read more

Get in touch.

Let us help you find your way.